Inactivated vaccine BBIBP-CorV (Sinopharm; 95% (95%CI: 94%,97%)) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech; 98% (95%CI: 86%,99%)) demonstrated protection against COVID-19 related hospitalizations from the Delta (B.1.617.2) variant. Ongoing efforts are necessary to target vaccine hesitancy and promote booster shots for protection against severe COVID-19 disease and arising variants of concern.

No abstract

IntroductionA rapid increase in COVID-19 cases due to the spread of the Delta and Omicron variants in vaccinated populations has raised concerns about the hospitalization risk associated with, and the effectiveness of, COVID-19 vaccines.MethodThis case–control study aims to determine the hospitalization risk associated with the inactivated BBIBP-CorV (Sinopharm) and mRNA BNT162b2 (Pfizer–BionTech) vaccines, and their effectiveness reducing the rate of hospital admission between 28 May 2021 and 13 January 2022, during the Delta and Omicron outbreaks. The estimation of vaccine effectiveness of 4,618 samples was based on the number of patients hospitalized at different vaccination statuses, adjusted for confounding variables.ResultsHospitalization risk increases in patients affected with the Omicron variant if patients are aged ≤ 18 years (OR 6.41, 95% CI 2.90 to 14.17; p < 0.001), and in patients affected with the Delta variant if they are aged > 45 years (OR 3.41, 95% CI 2.21 to 5.50; p < 0.001). Vaccine effectiveness reducing the rate of hospital admission for fully vaccinated participants infected with the Delta and Omicron variants was similar for both the BBIBP-CorV (94%, 95% CI 90% to 97%; 90%, 95% CI 74% to 96%) and BNT162b2 vaccines (95%, 95% CI 61% to 99.3%; 94%, 95% CI 53% to 99%), respectively.DiscussionThe BBIBP-CorV and BNT162b2 vaccines utilized in the UAE vaccination program were highly effective in reducing the rate of COVID-19-related hospitalization during the Delta and Omicron outbreaks, and further effort must be taken to achieve high vaccine coverage rates in children and adolescents in the global context to reduce the hospitalization risk associated with COVID-19 on an international scale.

In this work, we employed the Immersed Boundary-Lattice Boltzmann Method (IB-LBM) to simulate the motion of a microparticle in a microchannel under the influence of a standing surface acoustic wave (SSAW). To capture the response of the target microparticle in a straight channel under the effect of the SSAW, in-house code was built in C language. The SSAW creates pressure nodes and anti-nodes inside the microchannel. Here, the target particle was forced to traverse toward the pressure node. A mapping mechanism was developed to accurately apply the physical acoustic force field in the numerical simulation. First, benchmarking studies were conducted to compare the numerical results in the IB-LBM with the available analytical, numerical, and experimental results. Next, several parametric studies were carried out in which the particle types, sizes, compressibility coefficients, and densities were varied. When the SSAW is applied, the microparticles (with a positive acoustic contrast factor) move toward the pressure node locations during their motion in the microchannel. Hence, their steady-state locations are controlled by adjusting the pressure nodes to the desired locations, such as the centerline or near the microchannel sidewalls. Moreover, the geometric parameters, such as radius, density, and compressibility of the particles affect their transient response, and the particles ultimately settle at the pressure nodes. To validate the numerical work, a microfluidic device was fabricated in-house in the cleanroom using lithographic techniques. Experiments were performed, and the target particle was moved either to the centerline or sidewalls of the channel, depending on the location of the pressure node. The steady-state placements obtained in the computational model and experiments exhibit excellent agreement and are reported.